Failure to induce global or clinical remission · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in failure to induce global or clinical remission compared with conventional dosing (high certainty).
1 finding from 1 review
Failure to induce global or clinical improvement · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in failure to induce global or clinical improvement compared with conventional dosing (moderate certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in failure to induce endoscopic remission compared with conventional dosing (high certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in failure to adhere to medication regimen compared with conventional dosing (low certainty).
1 finding from 1 review
Adverse events · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in adverse events compared with conventional dosing (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in serious adverse events compared with conventional dosing (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in withdrawal due to adverse events compared with conventional dosing (low certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in failure to maintain clinical or endoscopic remission compared with conventional dosing (high certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in failure to adhere to study medication regimen compared with conventional dosing (moderate certainty).
1 finding from 1 review
Adverse event · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in adverse event compared with conventional dosing (high certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in serious adverse events compared with conventional dosing (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether once‐daily dosing changes withdrawal due to adverse events compared with conventional dosing (very low certainty).
1 finding from 1 review
Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in exclusion/withdrawal after entry compared with conventional dosing (high certainty).
1 finding from 1 review
Intervention not reported
Lung function Mean percentage change in FEV1 · adults and children with cystic fibrosis
1 finding from 1 review
Intervention not reported
Lung function Mean percentage change in FVC (% predicted) · adults and children with cystic fibrosis
1 finding from 1 review
Intervention not reported
Nutritional status BMI · adults and children with cystic fibrosis
1 finding from 1 review
Intervention not reported
Time to first exacerbation requiring intravenous antibiotics · adults and children with cystic fibrosis
1 finding from 1 review
Intervention not reported
Antibiotic resistance patterns following treatment · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Ototoxicity An increase in auditory threshold of 20 dB or more over any frequency range · adults and children with cystic fibrosis
The intervention showed no clear difference in ototoxicity An increase in auditory threshold of 20 dB or more over… (low certainty).
1 finding from 1 review
Intervention not reported
Nephrotoxicity The percentage change in creatinine over baseline · adults and children with cystic fibrosis
1 finding from 1 review